Fax: (011) 390516366761.
Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60†
Report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years
Article first published online: 11 JAN 2007
Copyright © 2006 American Cancer Society
Volume 109, Issue 4, pages 780–786, 15 February 2007
How to Cite
Bacci, G., Balladelli, A., Forni, C., Ferrari, S., Longhi, A., Bacchini, P., Alberghini, M., Fabbri, N., Benassi, M., Briccoli, A. and Picci, P. (2007), Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60. Cancer, 109: 780–786. doi: 10.1002/cncr.22456
Informed Consent was obtained from all patients in the study.
- Issue published online: 2 FEB 2007
- Article first published online: 11 JAN 2007
- Manuscript Accepted: 15 NOV 2006
- Manuscript Revised: 6 NOV 2006
- Manuscript Received: 28 SEP 2006
- Ewing sarcoma family tumors;
- neoadjuvant chemotherapy;
The clinical and pathologic features of 46 patients 40 to 60 years old with Ewing sarcoma family tumor (ESFT) diagnosed at the authors' institute between 1972 and 2000 were reviewed.
Ten patients with metastatic tumors at presentation went elsewhere for treatment; 35 of 36 remaining cases with localized disease were treated at the authors' institution according to different chemotherapy protocols activated in successive years. In patients with nonmetastatic tumors local treatment was surgery in 9 patients, radiotherapy in 16, and surgery followed by radiotherapy in 10.
At follow-up times ranging from 6 and 34 years (mean, 17.8 years), 15 patients (42.9%) remained continuously disease-free, 19 experienced recurrence, and 1 died of chemotherapy-related toxicity. The 5- and 10-year event-free survivals were 42.9% and 35.2%, respectively, and the 5- and 10-year overall survivals were 46.1% and 42.8%, respectively. Comparing this group of patients with 586 cases of younger patients seen in the same period at Rizzoli, the only difference between the 2 groups was a significantly higher rate of tumors located in the soft tissues with a larger volume in the older group. The results achieved were comparable in the 2 groups, although the older group had a lower chemotherapy dose-intensity and a higher rate of WHO grade 4 hematologic toxicity.
For patients with localized disease treated with adjuvant and neoadjuvant chemotherapy the results were essentially comparable in the 2 groups. It is concluded that patients 40 years or older with ESFT should be treated in the same way as younger patients and included in treatment trials for these tumors. Cancer 2007. © 2007 American Cancer Society.